# Spyre Therapeutics Inc. (SYRE) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $88.98, market value $7.8 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Spyre Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 8.2×**. The shares trade at 8.2× book value; most of the value is in earnings power and intangibles rather than the balance sheet.

## Profitability
- **Return on equity: -21.7%**. Return on equity is negative because earnings are negative.
- **Return on assets: -20.0%**. Each dollar of assets produces -20.0% of profit.

## Financial health
- **Current ratio: 13.25** (quick 13.25). Current assets cover the next year's liabilities 13.25 times.
- **Altman Z-score: 76.77**. A Z-score of 76.77 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Spyre Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (13 analysts). 13 analysts cover Spyre Therapeutics Inc.; the consensus is strong_buy, with an average price target of $119.69 (+35% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 423.7%** (YTD 171.6%, 3-mo 20.8%). The shares are up 423.7% over twelve months including dividends.
- **From 52-week high: -19.2%** (513.4% above the low). Trading 19% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 36**. An RSI of 36 is neutral.
- **Beta (1 yr): 1.83** (volatility 70%). Beta of 1.83 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SYRE · Page: https://foliofundamentals.com/stocks/syre

Not investment advice.